“This patent further strengthens our intellectual property, which will be important as others and are drawn into space,” said Minimus Spine’s President and CEO David Hooper. “The subject matter included in this patent issued in Europe and Australia last year and we are pleased to be granted similar protection in the United States.”
Here are five quick facts on the patent:
1. The syringe cartilage maintains sterility of the syringe while the devices is processed within the Triojection console.
2. Triojection produces and measures ozone in a sterile syringe — the only system doing so.
3. The system has a CE mark and was used in the first cases last year.
4. Triojection is an alternative to surgery for patients with leg pain associated with disc herniation.
5. The initial feedback on procedures preformed last year were positive and the company is progressing on the European post-market study that will randomize patients to compare outcomes and costs associated with Triojection and surgical discectomy.
More articles on orthopedic devices:
Lumin Health names two new executives
Medtronic, LDR, Smith & Nephew & more—25 key notes
5 key trends in the global bio-implants market
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
